Soken Chemical & Engineering, the Tokyo-listed adhesives and process-engineering maker, adopted a takeover-response plan on July 24, 2026, aimed at Axium Capital Pte. Ltd., a Singapore-based investor whose holding has climbed from 6.72% in November 2025 to 22.60% as of July 13, 2026. The board says Axium has not explained what it wants.
| Date | Filing | Stake |
|---|---|---|
| Oct 31, 2025 (reported Nov 10, 2025) | Initial large shareholding report | 6.72% |
| July 7-13, 2026 | Amendment No.9 / No.10 | 21.47% |
| July 13, 2026 (filed July 21, 2026) | Amendment No.11 | 22.60% |
Why 22.60% matters: Soken's board reckons that, given typical turnout of about 65% of voting shares at its annual meeting, a holder needs only around 20% of total voting rights to block a special resolution under the Companies Act. Axium is already past that line. The plan itself is triggered at a higher bar: any move to take voting rights to 23% or more counts as a "large-scale acquisition" subject to the new procedure.
Soken says it has held regular meetings with Axium since around August 2025, and before that with a predecessor entity, SWISS-ASIA Financial Services, since 2023, discussing its mid-term plan and capital allocation. Axium nonetheless ran a public campaign ahead of Soken's June 24, 2026 annual meeting urging shareholders to vote down the company's director and auditor nominees. They were all re-elected anyway, with 76.00% to 76.83% support for the director nominees and 75.37% for the auditor nominee, even though Axium alone cast 22.83% of the votes at that meeting against them.
On July 17, Soken wrote to Axium asking whether it intends further purchases, at what level, and for what purpose. As of July 24 it had received no reply.
How the trigger actually works
The plan does not automatically force a shareholder vote before Axium, or anyone else, can cross 23%. A buyer that follows the required steps, filing a large-scale acquisition statement 60 business days ahead of any move past the threshold and then supplying information the board requests within 10 business days, can proceed once the board's evaluation period ends. That window runs up to 60 business days and can be extended by another 20 on the independent committee's recommendation. A special shareholder meeting to test investor sentiment is convened only if the board decides to oppose the acquisition and put a countermeasure to a vote; absent that decision, the buyer is not otherwise required to wait for one.
The three-member independent committee, made up of outside directors Hiroki Izumi, Keiko Asano and Michiyuki Nakase, reviews the process and recommends whether to activate a countermeasure. Soken says the board will give the committee's recommendation "maximum respect", but the plan does not require the committee's formal sign-off before the board can act.
If a buyer ignores the notice procedure and tries to push past 23% anyway, the board can deploy the countermeasure, a warrant allotment that dilutes a disqualified holder's stake, without waiting for a shareholder vote.
The plan runs until the board meeting following Soken's June 2027 annual meeting, and the company says it does not intend to keep it in place once concerns about a specific acquirer fade. What Axium ultimately wants, and whether it will test the mechanism, is still not disclosed.